CRVS - Corvus - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

19.82M

Cash

37.02M

Avg Qtr Burn

-6.953M

Short % of Float

4.81%

Insider Ownership

4.09%

Institutional Own.

45.55%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Mupadolimab (CPI-006) (Anti-CD73) Details Renal cell carcinoma, Lung cancer, Cancer, Non-small cell lung carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib (CPI-818) (ITK inhibitor) Details Renal cell carcinoma, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ciforadenant (A2AR inhibitor) +/- ipilimumab and nivolumab Details Renal cell carcinoma, Lung cancer, Multiple myeloma, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab + pembrolizumab Details HPV+ oropharyngeal cancer, Head and neck cancer, Non-small cell lung carcinoma, Cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib (CPI-818) (ITK inhibitor) Details Cutaneous T cell lymphoma, Lymphoma, Cancer, Blood cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab (CPI-0060 (B-cell activation) (CD73 inhibitor) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.